Free shipping on all orders over $ 500

Crovalimab

Cat. No. M24849
Crovalimab Structure
Synonym:

SKY59; RO7112689

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.

Chemical Information
CAS Number 1917321-26-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Masanobu Nishidate, et al. Bioanalysis. Validation of a method to analyze size distribution of crovalimab-complement C5-eculizumab complexes in human serum

[2] Gianluigi Ardissino, et al. Pharmaceuticals (Basel). Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy

[3] Urszula Szlendak, et al. Pol Arch Intern Med. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment

[4] Jun-Ichi Nishimura, et al. Br J Haematol. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

[5] Alexander Röth, et al. Blood. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Related Complement System Products
P014

P014 is a C5 antibody/CFH fragment fusion protein that can be used in studies related to paroxysmal sleep hemoglobinuria (PNH) and thrombotic microangiopathy (TMA).

POT-4

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation.

TLQP-21

TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM).

N-((Allyloxy)carbonyl)-N-methyl-L-alanine

N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative.

C5a Receptor agonist, mouse, human

C5a Receptor agonist, mouse, human is a biological active peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: Crovalimab, SKY59; RO7112689 supplier, Complement System, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.